Quantinno Capital Management LP Boosts Stock Position in Smith & Nephew plc (NYSE:SNN)

Quantinno Capital Management LP grew its holdings in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 83.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 97,818 shares of the medical equipment provider's stock after buying an additional 44,592 shares during the quarter. Quantinno Capital Management LP's holdings in Smith & Nephew were worth $2,404,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. PNC Financial Services Group Inc. grew its stake in Smith & Nephew by 4.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider's stock worth $224,000 after acquiring an additional 399 shares in the last quarter. National Bank of Canada FI grew its position in shares of Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after buying an additional 446 shares in the last quarter. Bleakley Financial Group LLC increased its stake in shares of Smith & Nephew by 3.5% during the fourth quarter. Bleakley Financial Group LLC now owns 17,704 shares of the medical equipment provider's stock valued at $435,000 after buying an additional 596 shares during the period. Signaturefd LLC raised its holdings in shares of Smith & Nephew by 4.3% in the fourth quarter. Signaturefd LLC now owns 15,772 shares of the medical equipment provider's stock valued at $388,000 after acquiring an additional 653 shares in the last quarter. Finally, Principal Securities Inc. lifted its stake in Smith & Nephew by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 691 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew Stock Performance

Shares of NYSE SNN traded up $0.25 during trading on Monday, reaching $28.65. 948,581 shares of the company traded hands, compared to its average volume of 798,440. The stock has a market cap of $12.55 billion, a P/E ratio of 13.26, a PEG ratio of 1.26 and a beta of 0.68. The firm's fifty day simple moving average is $27.43 and its 200 day simple moving average is $26.40. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. Smith & Nephew plc has a 12-month low of $23.69 and a 12-month high of $31.72.

Smith & Nephew Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.447 per share. This is a boost from Smith & Nephew's previous semi-annual dividend of $0.29. The ex-dividend date is Friday, March 28th. This represents a dividend yield of 2.5%. Smith & Nephew's dividend payout ratio (DPR) is presently 41.20%.

Analyst Upgrades and Downgrades

SNN has been the topic of a number of research reports. Wall Street Zen raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. HSBC downgraded Smith & Nephew from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Canaccord Genuity Group upped their price objective on Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. UBS Group lowered Smith & Nephew from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Finally, Hsbc Global Res downgraded Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.00.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.